Aptamer Group plc logo

Aptamer Group plc (APTA)

Market Closed
17 Jul, 15:30
LSE LSE
£
0. 48
+0
+0.6316%
£
4.51M Market Cap
- P/E Ratio
- Div Yield
1.41M Volume
- Eps
£ 0.47
Previous Close
Add Transaction
Day Range
0.45 0.5
Year Range
0 0
Want to track APTA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

APTA closed Friday higher at £0.48, an increase of 0.6316% from Thursday's close, completing a monthly increase of 0% or £0.48. Over the past 12 months, APTA stock gained 0%.
APTA is not paying dividends to its shareholders.
The last earnings report, released on Nov 07, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on LSE (GBP).

APTA Chart

People also search for

Genflow Biosciences Plc
1.93 GBX
-0.7732%
Bsf Enterprise Plc
0.85 GBX
-2.8571%
ROQ
Roquefort Therapeutics plc
10 GBX
0%

Aptamer Group plc (APTA) FAQ

What is the stock price today?

The current price is £0.48.

On which exchange is it traded?

Aptamer Group plc is listed on LSE.

What is its stock symbol?

The ticker symbol is APTA.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 4.51M.

Has Aptamer Group plc ever had a stock split?

No, there has never been a stock split.

Aptamer Group plc Profile

Biotechnology Industry
Healthcare Sector
- CEO
LSE Exchange
GB00BNRRP542 ISIN
United Kingdom Country
37 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Aptamer Group plc is a pioneering company located in York, United Kingdom, recognized for its innovative work in the field of research, diagnostics, and therapeutics. Since its establishment in 2008, Aptamer Group has been dedicated to providing cutting-edge solutions globally, including in the United Kingdom and the rest of Europe. The company has carved a niche for itself by specializing in the development and application of oligonucleotide binders. Aptamer Group plc has cemented its reputation by servicing a wide range of clients, including leading pharmaceutical companies, developmental companies focusing on diagnostics, and various research institutes. Its services are tailored to meet the evolving demands of bioprocessing, diagnostic, and pharmaceutical scientists, leveraging the company’s proprietary Optimer platform for the discovery and development of oligonucleotide binders.

Products and Services

  • Optimer Platform:

    This flagship technology platform facilitates the discovery and development of oligonucleotide binders, known as Optimers. The Optimer platform stands out for its ability to yield high-affinity and specific nucleic acid-based aptamers, which are employed in various research and therapeutic applications. This platform underscores Aptamer Group's commitment to innovation in the life sciences sector.

  • Custom Development Services for Oligonucleotide-based Aptamer and Optimer Binders:

    Aptamer Group offers bespoke service packages for the development of customized oligonucleotide-based aptamer and Optimer binders. These personalized solutions cater to specific client needs, targeting a wide range of applications from diagnostics to therapy. The flexibility and adaptability of these services make them highly valuable to clients working in complex and diverse scientific fields.

  • Solutions for Bioprocessing, Diagnostic, and Pharmaceutical Scientists:

    The company delivers a suite of solutions tailored to the needs of bioprocessing, diagnostic, and pharmaceutical scientists. These solutions encompass a variety of applications, including but not limited to, therapeutic drug monitoring, biomarker discovery, and molecular diagnostics. Aptamer Group leverages its expertise to provide innovative and reliable solutions that advance scientific research and development.

  • Contract Research Services in the Field of Therapeutics:

    Aptamer Group extends its comprehensive expertise through contract research services, particularly focusing on the therapeutics domain. These services enable clients to navigate the complexities of therapeutic development with the support of a seasoned partner. By offering such services, Aptamer Group plays a crucial role in accelerating the pace of new therapeutic discoveries and their subsequent development.

Contact Information

Address: Windmill House
Phone: 44 19 0421 7404